Literature DB >> 8646923

[Is liver resection in metastases of exocrine pancreatic carcinoma justified?].

J Klempnauer1, G J Ridder, P Piso, R Pichlmayr.   

Abstract

From 1971 to 1995 we have performed 23 liver resections in 22 patients because of hepatic metastases of pancreatic (n = 20) or ampullary (n = 2) carcinomas. In 16 patients the hepatic secondaries were removed synchronously with the pancreatic primary tumour. In 7 cases liver resection was performed for metachronous metastases. Only one patient died after simultaneous resection of liver and pancreas (operative lethality 4,3%). Curative R0-resection was accomplished in 69% of patients with synchronous and 100% with metachronous liver metastases. The median survival time was 8,3 months after synchronous and 5,8 months after metachronous hepatic resection. The one-year survival amounted to 41 and 40% resp. Though distant metastases are a definite sign of a progressed tumour stage, the prognosis of patients with hepatic metastases should not be considered hopeless. In view of a comparatively small operative risk there is a chance for individual patients to gain valuable survival time.

Entities:  

Mesh:

Year:  1996        PMID: 8646923

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  10 in total

1.  Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence.

Authors:  Shailesh V Shrikhande; Savio G Barreto
Journal:  World J Gastrointest Surg       Date:  2010-02-27

Review 2.  Oligometastatic Disease in Pancreatic Cancer - How to Proceed?

Authors:  Bernhard W Renz; Stefan Boeck; Falk Roeder; Christoph Trumm; Volker Heinemann; Jens Werner
Journal:  Visc Med       Date:  2017-02-10

Review 3.  Advances in chemotherapy for pancreatic cancer.

Authors:  Bhawna Sirohi; Ashish Singh; Shaheenah Dawood; Shailesh V Shrikhande
Journal:  Indian J Surg Oncol       Date:  2015-01-13

Review 4.  Surgery for oligometastasis of pancreatic cancer.

Authors:  Fengchun Lu; Katherine E Poruk; Matthew J Weiss
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087

5.  Improved survival after palliative resection of unsuspected stage IV pancreatic ductal adenocarcinoma.

Authors:  Younghwan Kim; Song Cheol Kim; Ki Byoung Song; Jayoun Kim; Dae Ryong Kang; Jae Hoon Lee; Kwang-Min Park; Young-Joo Lee
Journal:  HPB (Oxford)       Date:  2016-02-08       Impact factor: 3.647

6.  The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma.

Authors:  F Klein; G Puhl; O Guckelberger; U Pelzer; J R Pullankavumkal; S Guel; P Neuhaus; M Bahra
Journal:  Gastroenterol Res Pract       Date:  2012-11-08       Impact factor: 2.260

7.  Palliative interventional and surgical therapy for unresectable pancreatic cancer.

Authors:  Volker Assfalg; Norbert Hüser; Christoph Michalski; Sonja Gillen; Jorg Kleeff; Helmut Friess
Journal:  Cancers (Basel)       Date:  2011-02-14       Impact factor: 6.639

8.  Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases?

Authors:  Rachael Chang Lee; Harsh Kanhere; Markus Trochsler; Vy Broadbridge; Guy Maddern; Timothy J Price
Journal:  World J Gastrointest Oncol       Date:  2018-08-15

9.  Treatment of hepatic pancreatic ductal adenocarcinoma metastases with high-dose-rate image-guided interstitial brachytherapy: a single center experience.

Authors:  Ralph Drewes; Jazan Omari; Matthias Manig; Max Seidensticker; Peter Hass; Jens Ricke; Maciej Powerski; Maciej Pech
Journal:  J Contemp Brachytherapy       Date:  2019-08-29

10.  Surgical margin clearance and extended chemotherapy defines survival for synchronous oligometastatic liver lesions of the ductal adenocarcinoma of the pancreas.

Authors:  S A Safi; G Fluegen; A Rehders; L Haeberle; S Fung; V Keitel; A Krieg; W T Knoefel; N Lehwald-Tywuschik
Journal:  Int J Clin Oncol       Date:  2021-06-16       Impact factor: 3.402

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.